• Aktis Oncology Chief Medical Officer Akos Czibere exercised stock options to acquire 50,000 common shares at USD 4.95 on July 8, 2026.
• Czibere sold 50,000 common shares the same day at weighted-average prices of about USD 27.13, USD 27.95, USD 28.71.
• He ended the day with no directly held common shares.
• He reported 221,218 stock options beneficially owned following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-300162), on July 10, 2026, and is solely responsible for the information contained therein.